What's Changing in Your Specialist Operations

Every COO or Head of Operations at a mid-sized European pharma affiliate has had the same Tuesday. Three active programmes on the senior regulatory director's desk. The Day 120 EMA response is due today. The PSUR review for the cardiometabolic programme is due Thursday. The Germany HTA package ships next week. The market access manager who joined in January is covering the fourth programme. The regulatory director has been in the firm for twenty-seven years. She knows the reviewers at three HTA bodies by name. She is the bottleneck, and the CEO asked about programme timelines in the last GMT.

You have managed this function long enough to know the pattern. The specialist bench that kept programmes moving has not grown at the same rate the programme load has. Your senior regulatory and market access professionals are spending roughly half their week on compilation, cross-referencing, and monitoring work that does not require their judgment. And you can name the two or three people whose departure would put a programme in jeopardy.

This is not a staffing problem. It is a capacity architecture problem. The preparation layer that consumes half your specialists' time has always been separable from the judgment layer. The firms redesigning that preparation layer now are running more programmes with the same bench, at the same quality, reaching market access timelines their peers cannot match.

This is an industry problem and a specialist-operations problem, arriving at the same time. The COOs who treat them as one are building a different kind of firm.

This briefing covers what is changing in life sciences operations, what it means inside your specialist bench, and the three questions your operations team should answer before the next programme review.

The EU HTA Regulation went live in January 2025 for oncology drugs and advanced therapy medicinal products. For the first time, a single clinical assessment covers all member states simultaneously. The evidence package that used to move through country-by-country filings in sequence now must be prepared for parallel review across regulatory affairs, market access, medical affairs, and commercial operations at the same time.

AI is compressing the early part of the value chain. Target identification timelines are down thirty to forty percent. Clinical phases remain biology-bound. The result is more programmes reaching the regulatory and market access phase simultaneously, putting capacity pressure on exactly the specialists who are hardest to replace. Discovery runs faster. The commercial and regulatory bottleneck deepens.

More programmes reaching the regulatory stage simultaneously. The same number of specialists. The same preparation-heavy model. The queue builds on the most expensive resources in the firm.

The firms moving ahead are not hiring faster. They have redesigned the preparation layer inside their specialist bench. Country-specific HTA package assembly, regulatory guideline monitoring, PSUR narrative compilation, and Day 120 response drafting run on structured infrastructure. Specialists own the judgment, the agency relationship, and the final output. The firms that made this shift are filing first-market HTA submissions three to four months faster than peers on the same clinical package. Three months of market access advantage in a reference-pricing environment is a commercial gap that compounds.

Your regulatory affairs function. Your regulatory directors and managers spend a significant share of each week on preparation work: monitoring guideline updates, compiling cross-reference tables, formatting submission packages, and drafting first-pass agency responses. That work is necessary. It is not where their judgment adds distinctive value. The director who spent four hours compiling a Day 120 response could have spent those hours on the argumentation and the agency relationship that actually determines the outcome.

Your market access function. Each national HTA submission requires a country-specific evidence package from the global clinical dossier. For Germany, France, England, Sweden, and three more markets simultaneously, that assembly is substantial. Your market access managers know the argumentation and the payer landscape. The assembly, formatting, and consistency-checking runs in parallel with the argumentation. Right now it runs on the same people.

Your medical affairs and pharmacovigilance function. Your MSLs carry scientific conversations that open doors no sales contact can. Your pharmacovigilance specialists own signal assessment and the regulatory narrative. Both have preparation layers: literature monitoring, case narrative compilation, PSUR database synthesis. This preparation occupies thirty to fifty percent of specialist time. The specialists doing it are the ones you cannot replace.

Your specialist bench. The regulatory directors, market access managers, and MSLs who carry programme knowledge took eight to fifteen years to develop. Specialist searches in regulatory affairs take nine to twelve months. When a programme needs cover because one specialist is at capacity, the solution is usually to overload another. The bench has no slack designed into it.

Your programme operations. Cross-functional coordination runs on shared calendars, email threads, and the judgment of whoever last read the latest agency guidance. The firms that have built structured programme infrastructure run four programmes in parallel at the team size that used to run two.

Your sector is adding programme volume because AI has accelerated discovery. Your specialist bench is not keeping pace because the preparation layer has never been separated from the judgment layer. Your regulatory director is brilliant. She is also compiling. Your market access team knows every HTA body's preferences. They are also assembling packages. Your pharmacovigilance lead can spot a safety signal at first reading. He is also mining databases.

You do not have three problems. You have one. The specialist judgment that makes your programmes succeed has never been separated from the person who carries it. Every cycle-time problem, every quality risk, every programme queue is a symptom of that single unsolved thing. Build the infrastructure to carry the preparation and the judgment becomes available for what it is actually worth.

The firms that made this shift are running more programmes with the same bench. Their seniors review rather than compile. Their juniors learn by working alongside structured precedent infrastructure from week one, not by spending two years in preparation tasks before they reach anything that builds judgment. The knowledge the 27-year regulatory director accumulated stops being biographical when it lives in the firm's infrastructure.

You have twelve to eighteen months before the HTA coordination pressure is fully visible in your programme timelines. The firms that redesigned the preparation layer in early 2026 will be filing earlier, reaching market access faster, and compounding capacity through the same period you are still deciding.

Every life sciences COO is thinking about capacity. Most are reaching the same four conclusions. A smaller group is reaching different ones. The difference is architecture, not headcount.

Three questions every life sciences COO is tracking. None of them used to be the same question. They are now.

Four concrete moves any life sciences COO can start this quarter. Each touches one part of the specialist bench. Pulled together, they become one architecture the firm runs on.

The life sciences COO has four places to go for help. None can do what we do, and each for a specific reason.

The big consulting firms' life sciences operations practices produce a diagnostic billed on the same specialist-hour model your firm runs on. They write the strategy. They cannot put working infrastructure into your regulatory team's submission workflow in eight weeks at a fixed fee.

The regulatory technology and knowledge management vendors sell a document repository with metadata tagging and version control. Document management is not knowledge extraction. Every life sciences COO has watched a Vault implementation solve traceability without solving what your regulatory director does with Tuesday morning.

The life sciences commercial analytics consultancies answer which market to enter and at what price. They do not answer how your market access team prepares the dossier for six HTA bodies while two specialists are already at capacity.

The hyperscaler life sciences consulting practices are platform-optimised. The agency precedents your regulatory team accumulates become a cloud asset, not a firm asset. That is lock-in with an expiry date.

The market offers four options you have already considered. GRAIL is the fifth.

We start with your operations leadership because the change cannot outrun the team's personal understanding of what is possible. Three workshops. Each delivers standalone value. Each earns the right to the next.

The questions where your team cannot agree on an answer are the ones worth an hour on the agenda.